Successful treatment of patients with refractory idiopathic membranous nephropathy with low-dose Rituximab: A single-center experience

Table 3 Comparison of clinical outcomes during follow-up

Outcome	0 (mo)	3 (mo)	6 (mo)	9 (mo)	12 (mo)
24 h UTP (g/d)	8.14 ± 6.05	5.65 ± 4.99	3.35 ± 3.20	1.74 ± 1.81a	1.24 ± 1.34a
ALB (g/L)	28.06 ± 8.42	32.39 ± 8.7	34.63 ± 7.69	36.84 ± 6.74a	40.93 ± 5.85b,c
Scr (μmol/L)	109.67 ± 40.87	97.38 ± 27.34	78.13 ± 16.49a	84.5 ± 16.96	90.5 ± 19.81
Remission rate (%)	—	56% (5/9)	67% (6/9)	89% (8/9)	89% (8/9)

^aP < 0.05 vs 0 mo.

^bP < 0.01 vs 0 mo.

^cP < 0.05 vs 3 mo.

Data were analysed by one-way ANOVA followed by post hoc LSD test (albumin and serum creatinine) and presented as the mean ± SD. Data were analysed by Kruskal Wallis H test (24 h urinary protein quantitation).

UTP: Urinary protein quantitation; ALB: Albumin; Scr: Serum creatinine.